ReviewCurrent neuropharmacology2016
A Potential Contribution of Chemokine Network Dysfunction to the Depressive Disorders.
Review in Current neuropharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Development of an Inflammation-related Gene-based Diagnostic Risk Model and Immune Infiltration Analysis in Bipolar Disorder.Current medicinal chemistry · 2026Article
- Improving genetic variant identification for quantitative traits using ensemble learning-based approaches.BMC genomics · 2025Article
- Anti-Neuroinflammatory Effects of a Macrocyclic Peptide-Peptoid Hybrid in Lipopolysaccharide-Stimulated BV2 Microglial Cells.International journal of molecular sciences · 2024Article
- Neurobehavioral protective effects of Japanese sake yeast supplement against chronic stress-induced anxiety and depression-like symptoms in mice: Possible role of central adenosine receptors.Psychopharmacology · 2024Article
- Evaluation of serum interleukin-12 and interleukin-4 as potential biomarkers for the diagnosis of major depressive disorder.Scientific reports · 2024Article
- Microglial Inflammatory Responses to SARS-CoV-2 Infection: A Comprehensive Review.Cellular and molecular neurobiology · 2023Review
- Sex-specific associations between plasma interleukin-6 and depression in persons with and without HIV.Brain, behavior, & immunity - health · 2023Article
- New insights into effects of Kaixin Powder on depression via lipid metabolism related adiponectin signaling pathway.Chinese herbal medicines · 2023Article
- Fractalkine/CX3CR1-Dependent Modulation of Synaptic and Network Plasticity in Health and Disease.Neural plasticity · 2023Review
- Serum CC Chemokines as Potential Biomarkers for the Diagnosis of Major Depressive Disorder.Psychology research and behavior management · 2022Article
- Analysis of Differentially Expressed Genes That Aggravate Metabolic Diseases in Depression.Life (Basel, Switzerland) · 2021Article
- Chemokines gene expression in the prefrontal cortex of depressed suicide victims and normal control subjects.Brain, behavior, and immunity · 2021Article
- On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos?Journal of neuroinflammation · 2021Review
- Fractalkine, sICAM-1 and Kynurenine Pathway in Restrictive Anorexia Nervosa-Exploratory Study.Nutrients · 2021Article
- Identification of Gene Co-Expression Modules and Core Genes Related to Immune Disorders in Major Depression Disorder.International journal of general medicine · 2021Article
- The Chemokine CXCL14-like Immunoreactivity Co-exists with Somatostatin, but not NPY in the Rat Dorsal Horn and Has Intimate Association with GABAergic Neurons in the Lateral Spinal Nucleus.Acta histochemica et cytochemica · 2020Article
- Serum levels of chemokines in adolescents with major depression treated with fluoxetine.World journal of psychiatry · 2020Article
- Screening TCGA database for prognostic genes in lower grade glioma microenvironment.Annals of translational medicine · 2020Article
- The Potential Role of Dysfunctions in Neuron-Microglia Communication in the Pathogenesis of Brain Disorders.Current neuropharmacology · 2020Review
- Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In spite of many years of research, the pathomechanism of depression has not yet been elucidated. Among many hypotheses, the immune theory has generated a substantial interest. Up till now, it has been thought that depression is accompanied by the activation of inflammatory response and increase in pro-inflammatory cytokine levels. However, recently this view has become controversial, mainly due to the family of small proteins called chemokines. They play a key role in the modulation of peripheral function of the immune system by controlling immune reactions, mediating immune cell communication, and regulating chemotaxis and cell adhesion. Last studies underline significance of chemokines in the central nervous system, not only in the neuromodulation but also in the regulation of neurodevelopmental processes, neuroendocrine functions and in mediating the action of classical neurotransmitters. Moreover, it was demonstrated that these proteins are responsible for maintaining interactions between neuronal and glial cells both in the developing and adult brain also in the course of diseases. This review outlines the role of chemokine in the central nervous system under physiological and pathological conditions and their involvement in processes underlying depressive disorder. It summarizes the most important data from experimental and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.